- Home
- CPF vs AVTX Comparison
CPF vs AVTX Comparison
Compare CPF & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPF | AVTX |
|---|---|---|
| Founded | 1954 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 997.1M | 956.7M |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CPF | AVTX |
|---|---|---|
| Price | $38.29 | $19.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $37.00 | ★ $40.57 |
| AVG Volume (30 Days) | 156.6K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | 45.18 | ★ 72.07 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $51,817,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $48.91 | ★ N/A |
| Revenue Growth | 33.81 | ★ 2312.27 |
| 52 Week Low | $25.62 | $4.73 |
| 52 Week High | $39.20 | $24.27 |
Technical Indicators
Market Signals| Indicator | CPF | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 59.02 |
| Support Level | $33.33 | $13.13 |
| Resistance Level | $39.20 | $20.72 |
| Average True Range (ATR) | 0.89 | 1.48 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 76.72 | 74.58 |
Price Performance
Historical ComparisonAbout CPF Central Pacific Financial Corp New
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.